Severe disorders of neurodevelopment have a substantial impact on the lives of affected individuals and their caregivers. The medical nomenclature used to describe these disorders can be a source of confusion in both clinical and research practice. Recognition and reporting of the global pattern of perturbation in development (for example, receptive and expressive language, social interactions), neurology (for example, dystonia, hypotonia, seizure type), morphology (for example, pre-and postnatal growth, facial dysmorphisms) and behavior (for example, stereotypies, attention deficit) is crucial. Given the number of different clinical disciplines to which a child may present-neurology, psychology, psychiatry, developmental pediatrics, clinical genetics-it is not surprising that biases exist between cohorts, with individuals having very different disorders being classified together. Although they are useful for targeting therapeutic strategies, some increasingly broad clinical groupings such as ASD-if defined solely on the basis of specific developmental and behavioral domain impairment-can present particular problems for clinical genetics research in terms of etiological heterogeneity.
There is increasing evidence that severe developmental disorders are primarily genetically determined. This provides an exciting opportunity to shift the current research paradigm toward 'sequencing first' , using samples from many individuals who have undergone unbiased clinical assessment to define the phenotypic space around comparable genotypes at specific loci. On page 515 of this issue 1 , Evan Eichler and colleagues use both clinically and genetically defined approaches to study neurodevelopmental disorders (NDDs) and find merit in both.
Large-scale sequencing
The use of trio-based whole-exome 2-9 or whole-genome 10 sequencing has enabled very rapid progress to be made in statistically robust linkage of de novo mutations in a large (and still growing) set of genes to the causation of NDDs. Stessman et al. 1 selected 208 genes in which de novo mutations had been implicated in NDD at various levels of confidence in the studies cited above. The use of molecular inversion probes (MIPs) for resequencing has a well-deserved reputation as a cost-effective, scalable approach to screening moderately sized gene panels in case cohorts 11, 12 . Here the authors designed a MIP pool that covered the entire coding region of each candidate gene. Using a predominantly proband-only sequencing strategy, they identified >2,000 private variants with plausibly deleterious consequences. The limited availability of parental samples meant that inheritance could be established for only ~13% of the variants. By combining the 138 disease-associated de novo mutations identified in this study with those from published studies, they found 91 different genes to be significantly enriched for de novo mutations. For comparison, 94 genes achieved genome-wide significance for de novo mutation occurrence in the first ~4,300 trios within the Deciphering Developmental Disorders (DDD) study 4 , with only 34 genes present in both lists. This low degree of overlap is likely to reflect the different inclusion criteria but may also reflect the different statistical models used for analysis.
Ten of the genes identified by Stessman et al. harbored only nonsynonymous variants, seven of which had multiple de novo substitutions altering the same residue (in some cases, precisely the same mutation), with activating or dominant-negative effects on the protein product. Light inspection of Supplementary Table 2 identified two individuals with previously reported de novo activating nonsynonymous variants in a known ID/DD-related gene (SMAD4; p.Ile500Val) 13 and recurrent substitutions in a plausible but very large candidate gene (TRRAP; p.Trp1866Arg and p.Trp1866Cys). This latter example underlines the importance of developing reliable © 2017 Nature America, Inc., part of Springer Nature. All rights reserved.
So, finally, the question arises: what is the best way to identify new disease-associated genes or mechanisms in developmental disorders? Inevitably, there is no simple answer (Fig. 1b) . That said, some general rules are emerging from this and other recent studies. Whenever possible, parental samples with cognate phenotypic information should be available, as this allows investigators to both establish and interpret the inheritance of each plausible causative variant. There are very substantial monetary cost savings from the use of focused gene panels (Fig. 1b) , which facilitate screening of very large numbers of affected individuals. However, the merits of scale can be undermined by limited coverage of the genomic space, given that a more plausible causative variant may exist in a gene that is not in the panel. As the catalog of known disease-associated genes becomes more complete, the likelihood of false positive diagnoses using gene panels will lessen. Currently, trio-based wholeexome sequencing probably represents the 'sweet spot' for cost-effective gene discovery for developmental disorders, but this will change and it is important to encourage a diversity of approaches to locus discovery, provided that statistically robust approaches and clinically well-characterized case cohorts are employed.
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phenotypic comparison using 25 of the genes. Such analyses are to be encouraged, as they have great potential to establish genotypediscriminative patterns in NDD that may be useful in filtering variants from whole-exome or whole-genome sequencing on the basis of the characteristics of the individual who has been sequenced. Mechanistically, genes with similar patterns of phenotypic effect may also share cellular and/or developmental functions. Maximizing the utility of phenotypic data requires the establishment of minimal sets of clinical and developmental data and the recording of these in meta-analysis-friendly formats. The use of a common structured language, such as Human Phenotype Ontology (HPO) 14 , to describe clinical features and the reporting of quantitative data in unambiguous formats (for example, growth in measurement units rather than centiles) seems a reasonable place to start. statistical tests that differentiate de novo recurrent functional substitutions from those that are the consequence of de novo mutations at hypermutable genomic sites. If this can be achieved, recurrent substitutions have considerable potential to identify new loci and/or mechanisms in neurodevelopmental disease.
Refining phenotypes
A particularly intriguing feature of this study is the attempt to differentiate, on genetic grounds, the main recruitment classes of ASD and ID/DD. The authors identified 8 genes with ASD bias and 17 genes with ID/ DD bias (Fig. 1a) , although, notably, none could be assigned exclusively to one category or the other. Applying a similar approach to the phenotypic data showed macrocephaly as enriched in ASD and microcephaly, seizures and malformations as enriched in ID/DD. The authors proceeded to a more detailed Cost-benefit assessment of three major strategies for discovering highly penetrant loci causing NDD (trio-based analysis using either whole-genome or wholeexome sequencing, and gene panel MIP capture and sequencing). The y axis is plotted on a log 10 scale. WGS, whole-genome sequencing. 
